TGCT
MCID: TST021
MIFTS: 60

Testicular Germ Cell Tumor (TGCT)

Categories: Cancer diseases, Fetal diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Testicular Germ Cell Tumor

MalaCards integrated aliases for Testicular Germ Cell Tumor:

Name: Testicular Germ Cell Tumor 56 52 58 73 17 71
Spermatocytic Seminoma 58 73 6 71
Male Germ Cell Tumor 56 73 13 71
Testicular Teratoma 58 54 17
Yolk Sac Tumor 58 54 71
Male Germ Cell Tumor, Somatic 56 6
Germ Cell Tumor of Testis 52 58
Embryonal Cell Carcinoma 73 71
Endodermal Sinus Tumor 58 73
Seminoma 73 71
Tgct 56 73
Mgct 56 73
Malignant Testicular Non-Seminomatous Germ Cell Tumor 71
Testicular Non-Dysgerminomatous Germ Cell Tumor 58
Non-Dysgerminomatous Germ Cell Tumor of Testis 58
Testicular Non Seminomatous Germ Cell Tumor 58
Testicular Non-Seminomatous Germ Cell Tumor 71
Non-Seminomatous Germ Cell Tumor of Testis 58
Testicular Seminomatous Germ Cell Tumor 58
Seminomatous Germ Cell Tumor of Testis 58
Nonseminomatous Germ Cell Tumors 73
Spermatocytic Seminoma, Somatic 56
Nonseminomatous Germ Cell Tumor 71
Tumor, Germ Cell, Testicular 39
Male Germ Cell Tumor; Mgct 56
Germ Cell Tumors, Somatic 56
Testicular Tumor, Somatic 56
Embryonal Carcinoma Cell 17
Teratoma of the Testis 58
Testicular Seminoma 58
Teratoma Testicular 73
Seminoma of Testis 58
Teratoma of Testis 71

Characteristics:

Orphanet epidemiological data:

58
testicular seminomatous germ cell tumor
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-5/10000 (Europe); Age of onset: Adult; Age of death: adult,elderly,young Adult;
non-seminomatous germ cell tumor of testis
Prevalence: 1-9/100000 (Europe),1-5/10000 (Europe);
testicular teratoma
Prevalence: <1/1000000 (Europe);
spermatocytic seminoma
Prevalence: <1/1000000 (Europe); Age of onset: Adolescent,Adult; Age of death: normal life expectancy;

OMIM:

56
Inheritance:
somatic mutation

Miscellaneous:
two subtypes - seminoma and nonseminoma
occasionally germ cell tumor arise from extra gonadal site (e.g., mediastinum, retroperitoneum, pineal gland)
most common cancer in men aged 15-40 years
highest incidence in men of european descent
risk factors for development of tgct - family history, cryptorchidism , testicular feminization , klinefelter syndrome, previous tgct, gonadal dysgenesis


HPO:

31
testicular germ cell tumor:
Inheritance somatic mutation sporadic


Classifications:

Orphanet: 58  
Rare urogenital diseases


External Ids:

OMIM 56 273300
ICD10 via Orphanet 33 C56 C62.1 C62.9
UMLS via Orphanet 72 C0014145 C0036631 C0238451 more
UMLS 71 C0014145 C0036631 C0238451 more

Summaries for Testicular Germ Cell Tumor

OMIM : 56 Testicular germ cell tumors (TGCTs) affect 1 in 500 men and are the most common cancer in males aged 15 to 40 in western European populations. The incidence of TGCT rose dramatically during the 20th century. Known risk factors for TGCT include a history of undescended testis (UDT), testicular dysgenesis, infertility, previously diagnosed TGCT, and a family history of the disease. Brothers of men with TGCT have an 8- to 10-fold risk of developing TGCT, whereas the relative risk to fathers and sons is 4-fold. This familial relative risk is much higher than that for most other types of cancer (summary by Rapley et al., 2000). (273300)

MalaCards based summary : Testicular Germ Cell Tumor, also known as spermatocytic seminoma, is related to childhood endodermal sinus tumor and extragonadal seminoma. An important gene associated with Testicular Germ Cell Tumor is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Downstream signaling events of B Cell Receptor (BCR) and MicroRNAs in cancer. The drugs Captopril and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include testis, bone and bone marrow, and related phenotypes are abnormality of metabolism/homeostasis and cryptorchidism

UniProtKB/Swiss-Prot : 73 Testicular germ cell tumor: A common malignancy in males representing 95% of all testicular neoplasms. TGCTs have various pathologic subtypes including: unclassified intratubular germ cell neoplasia, seminoma (including cases with syncytiotrophoblastic cells), spermatocytic seminoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratoma.

Related Diseases for Testicular Germ Cell Tumor

Diseases in the Testicular Germ Cell Tumor family:

Testicular Germ Cell Tumor 1

Diseases related to Testicular Germ Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 801)
# Related Disease Score Top Affiliating Genes
1 childhood endodermal sinus tumor 35.0 MIR371A AFP
2 extragonadal seminoma 34.5 KIT AFP
3 mediastinum seminoma 34.4 KIT AFP
4 testicular cancer 33.2 STK11 SPRY4 KITLG DMRT1 AFP
5 testicular germ cell cancer 32.7 SPRY4 MIR373 MIR372 MIR371A MIR367 KITLG
6 mixed germ cell cancer 32.5 MIR371A KIT AFP
7 teratoma 32.2 KIT FGFR3 DMRT1 AFP
8 seminoma 32.1 KIT HRAS FGFR3 DMRT1 AFP
9 endodermal sinus tumor 32.1 MIR371A KIT AFP
10 mature teratoma 31.7 MIR371A KIT AFP
11 mixed germ cell tumor 31.6 KIT AFP
12 testicular spermatocytic seminoma 31.4 HRAS FGFR3
13 thymoma, familial 31.2 KIT HRAS
14 spermatocytoma 31.2 MIR371A KIT FGFR3 DMRT1 AFP
15 cryptorchidism, unilateral or bilateral 31.1 SPRY4 KITLG KIT HRAS DMRT1 AFP
16 ovarian mixed germ cell neoplasm 31.0 KIT AFP
17 brain germinoma 31.0 SPRY4 KIT AFP
18 intratubular embryonal carcinoma 31.0 KIT AFP
19 mixed germ cell-sex cord neoplasm 30.9 KIT DMRT1
20 adult teratoma 30.8 HRAS AFP
21 ovarian gonadoblastoma 30.8 KIT DMRT1 AFP
22 dowling-degos disease 1 30.7 STK11 KITLG KIT FGFR3
23 germinoma 30.7 MIR371A KIT AFP
24 acinar cell carcinoma 30.7 STK11 BCL10 AFP
25 dysgerminoma of ovary 30.6 MIR371A KITLG KIT AFP
26 wilms tumor 1 30.6 MIR373 KIT HRAS AFP
27 malignant teratoma 30.5 MIR371A KIT AFP
28 gastrointestinal stromal tumor 30.4 MIR133B KITLG KIT FGFR3
29 mediastinal cancer 30.4 KIT AFP
30 dysgerminoma 30.4 MIR371A KITLG KIT DMRT1 AFP
31 pediatric germ cell cancer 30.3 SPRY4 MIR371A KITLG DMRT1 AFP
32 mast-cell sarcoma 30.3 KITLG KIT
33 large cell carcinoma 30.2 STK11 KIT HRAS
34 testicular disease 30.2 SPRY4 MIR371A KITLG KIT DMRT1 AFP
35 ovarian germ cell cancer 29.9 KIT AFP
36 germ cell cancer 29.9 SPRY4 MIR373 MIR372 MIR371A MIR367 MIR302D
37 rectum cancer 29.8 MIR371A MIR145 HRAS
38 leukemia, chronic lymphocytic 29.3 MIR373 MIR145 MIR140 KIT HRAS BCL10
39 gastrointestinal system disease 29.2 MIR373 MIR371A MIR200C MIR145 MIR140
40 lung cancer susceptibility 3 29.2 STK11 MIR200C MIR145 MIR140 KIT HRAS
41 leukemia, acute myeloid 29.1 MIR372 MIR367 MIR302D MIR145 MIR140 KITLG
42 testicular germ cell tumor 1 12.8
43 extragonadal nonseminomatous germ cell tumor 12.8
44 ovarian endodermal sinus tumor 12.7
45 pediatric testicular germ cell tumor 12.7
46 vaginal yolk sac tumor 12.7
47 adult endodermal sinus tumor 12.7
48 childhood ovarian endodermal sinus tumor 12.7
49 pineal region yolk sac tumor 12.7
50 testicular germ cell tumor non-seminomatous 12.6

Graphical network of the top 20 diseases related to Testicular Germ Cell Tumor:



Diseases related to Testicular Germ Cell Tumor

Symptoms & Phenotypes for Testicular Germ Cell Tumor

Human phenotypes related to Testicular Germ Cell Tumor:

31 (show all 7)
# Description HPO Frequency HPO Source Accession
1 abnormality of metabolism/homeostasis 31 HP:0001939
2 cryptorchidism 31 HP:0000028
3 azoospermia 31 HP:0000027
4 gonadal dysgenesis 31 HP:0000133
5 teratoma 31 HP:0009792
6 choriocarcinoma 31 HP:0100768
7 carcinoma 31 HP:0030731

Symptoms via clinical synopsis from OMIM:

56
Genitourinary Internal Genitalia Male:
painless testicular mass

Laboratory Abnormalities:
isochromosome 12p (i(12p))
elevated hcg (choriocarcinoma)
elevated afp (endodermal sinus tumor)
elevated hcg or afp or both (embryonal carcinoma)
azoospermia/oligospermia (present at diagnosis)

Neoplasia:
male germ cell tumors (gct), 2 subtypes -
seminoma
nonseminoma (embryonal carcinoma, teratoma, choriocarcinoma, endodermal sinus tumor)

Clinical features from OMIM:

273300

Drugs & Therapeutics for Testicular Germ Cell Tumor

Drugs for Testicular Germ Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 260)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Captopril Approved Phase 3 62571-86-2 44093
2
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
3
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
4
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
5
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
6
Ribavirin Approved Phase 3 36791-04-5 37542
7
Palivizumab Approved, Investigational Phase 3 188039-54-5
8
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
9
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
10
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
11
Ondansetron Approved Phase 3 99614-02-5 4595
12
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
13
Ofloxacin Approved Phase 3 82419-36-1 4583
14
Acyclovir Approved Phase 3 59277-89-3 2022
15
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
16
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
18
Etoposide Approved Phase 3 33419-42-0 36462
19
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
20
Mesna Approved, Investigational Phase 3 3375-50-6 598
21
Promethazine Approved, Investigational Phase 3 60-87-7 4927
22
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
23
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
24
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 6857599 5310940 9887054
25
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
26
Ifosfamide Approved Phase 3 3778-73-2 3690
27
Vinblastine Approved Phase 3 865-21-4 241903 13342
28
Histamine Approved, Investigational Phase 3 51-45-6 774
29
Cyproheptadine Approved Phase 3 129-03-3 2913
30
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
31
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
32
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
33
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
34
Polyestradiol phosphate Approved Phase 3 28014-46-2
35
Mycophenolic acid Approved Phase 3 24280-93-1 446541
36
Methionine Approved, Nutraceutical Phase 3 63-68-3 6137
37
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
38
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
39
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
40 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
41 Tocotrienol Investigational Phase 3 6829-55-6
42 Liver Extracts Phase 3
43 Antihypertensive Agents Phase 3
44 Angiotensin-Converting Enzyme Inhibitors Phase 3
45 HIV Protease Inhibitors Phase 3
46
protease inhibitors Phase 3
47 Cytochrome P-450 Enzyme Inhibitors Phase 3
48
Hydroxyitraconazole Phase 3
49 Antifungal Agents Phase 3
50 Cytochrome P-450 CYP3A Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 203)
# Name Status NCT ID Phase Drugs
1 Randomized Phase II/III Study of Taxol/Paclitaxel-BEP Versus BEP in Patients With Intermediate Prognosis Germ Cell Cancer Unknown status NCT00003643 Phase 2, Phase 3 cisplatin;etoposide;paclitaxel
2 A Study to Investigate the Efficacy and Tolerability of Two Dose Levels of Lerisetron Compared With Granisetron in Patients Receiving Radiotherapy for Stage I Seminoma Unknown status NCT00004219 Phase 3 granisetron hydrochloride;lerisetron
3 Trial of Imaging and Schedule in Seminoma Testis Unknown status NCT00589537 Phase 3
4 A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors Unknown status NCT00053352 Phase 3 cisplatin;etoposide
5 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
6 INTERNATIONAL RANDOMIZED STUDY FOR THE SALVAGE TREATMENT OF GERM CELL TUMOURS Unknown status NCT00002566 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;ifosfamide;vinblastine sulfate
7 Protocol for the Treatment of Extracranial Germ Cell Tumours in Children and Adolescents (GC III) Unknown status NCT00274950 Phase 3 carboplatin;cisplatin;etoposide;ifosfamide;vinblastine sulfate
8 RANDOMIZED MULTIINSTITUTIONAL PHASE III TRIAL OF BEP AND HIGH DOSE CHEMOTHERAPY VERSUS BEP ALONE IN PREVIOUSLY UNTREATED PATIENTS WITH POOR RISK GERM CELL TUMORS Completed NCT00002596 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide
9 A Randomized Phase III Study of Sequential High-Dose Cisplatinum/Etoposide/Ifosfamide Plus Stem Cell Support Versus BEP in Patients With Poor Prognosis Germ Cell Cancer Completed NCT00003941 Phase 3 cisplatin;etoposide;ifosfamide
10 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
11 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
12 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
13 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
14 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
15 Carboplatin in the Adjuvant Treatment of Stage I Seminoma: A Radomized Comparison of Single Agent Carboplatin With Radiotherapy in the Adjuvant Treatment of Stage I Seminoma of the Testis, Following Orchidectomy Completed NCT00003014 Phase 3 carboplatin
16 A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis Completed NCT00016380 Phase 3 dexamethasone;ondansetron
17 A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children Completed NCT00716976 Phase 3 sodium thiosulfate
18 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
19 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
20 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
21 Double Blind Randomised Controlled Trial to Investigate the Efficacy of ANTOX (Vers) 1.2 and MGCT (Magnesiocard) for the Treatment of Hereditary Pancreatitis and Idiopathic Chronic Pancreatitis Completed NCT00142233 Phase 3 Magnesium
22 A Randomized Phase III Toxicity Study of Day 2, 3, 8, 15 Short (30 Minute) Versus Day 1, 2, 3 Long (72 Hours) Infusion Bleomycin for Patients With IGCCCG Good Prognosis Germ Cell Tumors, TE3 Completed NCT00324298 Phase 3 cisplatin;etoposide
23 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
24 SIOP Intracranial Germ Cell Tumours Protocol Completed NCT00293358 Phase 3 carboplatin;cisplatin;etoposide phosphate;ifosfamide
25 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
26 A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors Recruiting NCT02375204 Phase 3 paclitaxel;ifosfamide;cisplatin;pegylated G-CSF;G-CSF;carboplatin;etoposide phosphate
27 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors Recruiting NCT03067181 Phase 3 Bleomycin;Carboplatin;Cisplatin;Etoposide;Etoposide Phosphate
28 A Randomized Phase III Study Comparing One Course of Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) and One Course of Carboplatin AUC7 in Clinical Stage I Seminomatous Testicular Cancer Recruiting NCT02341989 Phase 3 Bleomycin Etoposide and Cisplatin;Carboplatin
29 A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Active, not recruiting NCT00104676 Phase 3 cisplatin;etoposide;ifosfamide;oxaliplatin;paclitaxel
30 A Single Group Trial Evaluating One Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Tumours of the Testis (NSGCTT) Active, not recruiting NCT01726374 Phase 3 BEP(500)
31 A Randomized Phase III Study of Paclitaxel, Ifosfamide and Cisplatin Versus Vinblastine, Ifosfamide and Cisplatin as Second-Line Therapy for Patients With Relapsed/Resistant Germ Cell Tumors Terminated NCT00072215 Phase 3 cisplatin;ifosfamide;paclitaxel;vinblastine
32 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
33 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
34 A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
35 Phase I/II Multicentre Trial of Salvage Chemotherapy With Gem-TIP for Relapsed Germ Cell Cancer Unknown status NCT00551122 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;ifosfamide;paclitaxel
36 Tandem High-Dose Chemotherapy (HDCT) With Peripheral-Blood Stem-Cell Rescue for Patients With Metastatic Germ-Cell Tumors Failing First-Line Treatment Unknown status NCT01172912 Phase 2 carboplatin;cisplatin;dexamethasone;etoposide;ifosfamide
37 A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors Unknown status NCT02115165 Phase 2 Cabazitaxel
38 A Study of Paclitaxel, Cisplatin and Ifosfamide as Induction Therapy in the Treatment of Patients Relapsing After BEP Chemotherapy for Metastatic Germ Cell Tumors Completed NCT00004077 Phase 2 cisplatin;ifosfamide;paclitaxel
39 A Phase II Study of BMS-247550 In Advanced Germ Cell Tumor Patients - THERAPEUTIC/DIAGNOSTIC PROTOCOL Completed NCT00070096 Phase 2 ixabepilone
40 A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors Completed NCT00453310 Phase 2 sunitinib malate
41 Accelerated BEP Chemotherapy for Intermediate and High Risk Metastatic Germ Cell Tumor Completed NCT00453232 Phase 2 cisplatin;etoposide
42 Phase II Trial of Paclitaxel, Ifosfamide, and Cisplatin in Previously Untreated Intermediate and Poor Risk Germ Cell Tumor Patients Completed NCT00470366 Phase 2 cisplatin;ifosfamide;paclitaxel
43 Tandem High-Dose Chemotherapy With Autologous Stem Cell Rescue for Poor-Prognosis Germ Cell Cancer Completed NCT00002931 Phase 2 carboplatin;etoposide;ifosfamide;paclitaxel
44 Combination of Interleukin 11 (Neumega) With G-CSF to Mobilize Autologous Peripheral Blood Stem Cells (PBSC) Completed NCT00004157 Phase 2
45 Donor Lymphocyte Infusion (DLI) as Adoptive Immunotherapy for Relapse Malignancies After Allogeneic Hematopoietic Transplantation Completed NCT00003887 Phase 2
46 Oral Beclomethasone Dipropionate Capsules for Treatment of Intestinal Graft-Versus-Host Disease: Compassionate Use in Patients With Contraindictions to High-Dose Immunosuppressive Therapy Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
47 Cytokine-Based Immunotherapy Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation Completed NCT00003408 Phase 2
48 A PHASE II STUDY OF CELLULAR ADOPTIVE IMMUNOTHERAPY AS PROPHYLAXIS FOR CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION Completed NCT00002673 Phase 2
49 Randomized Phase II Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP Chemotherapy in Poor Prognosis Male Germ Cell Tumors Completed NCT00301782 Phase 2 carboplatin;cisplatin;etoposide phosphate;vincristine sulfate
50 PHASE II TRIAL WITH DOCETAXEL IN PATIENTS WITH RELAPSING GERM CELL CANCER Completed NCT00002903 Phase 2 docetaxel

Search NIH Clinical Center for Testicular Germ Cell Tumor

Genetic Tests for Testicular Germ Cell Tumor

Anatomical Context for Testicular Germ Cell Tumor

MalaCards organs/tissues related to Testicular Germ Cell Tumor:

40
Testis, Bone, Bone Marrow, Brain, Lymph Node, Thyroid, T Cells

Publications for Testicular Germ Cell Tumor

Articles related to Testicular Germ Cell Tumor:

(show top 50) (show all 939)
# Title Authors PMID Year
1
Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. 56 6
19855393 2009
2
Mutations of BRAF and RAS are rare events in germ cell tumours. 6 56
15386408 2005
3
Point mutations and deletions of the Bcl10 gene in solid tumors and malignant lymphomas. 6 56
10582682 1999
4
Lack of Bcl10 mutations in testicular germ cell tumours and derived cell lines. 56 6
10408400 1999
5
Lack of BCL10 mutations in germ cell tumors and B cell lymphomas. 6 56
10380920 1999
6
Activating c-kit gene mutations in human germ cell tumors. 56 6
10362788 1999
7
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. 56 6
9989495 1999
8
Somatic mutations in LKB1 are rare in sporadic colorectal and testicular tumors. 6 56
9605748 1998
9
Rare de novo germline copy-number variation in testicular cancer. 61 56
22863192 2012
10
Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. 56 61
20543847 2010
11
Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype. 56 61
20228134 2010
12
A genome-wide association study of testicular germ cell tumor. 56 61
19483681 2009
13
Deletion of eIF2beta suppresses testicular cancer incidence and causes recessive lethality in agouti-yellow mice. 56 61
19168544 2009
14
Association of BCL10 germ line polymorphisms on chromosome 1p with advanced stage testicular germ cell tumor patients. 61 56
16229939 2006
15
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. 61 56
16380914 2005
16
Codon-specific translation reprogramming promotes resistance to targeted therapy. 6
29925953 2018
17
A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. 6
28854169 2017
18
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. 6
25079330 2014
19
Copper is required for oncogenic BRAF signalling and tumorigenesis. 6
24717435 2014
20
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. 6
24670642 2014
21
Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. 6
24512911 2014
22
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. 6
23685455 2013
23
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. 6
23302800 2013
24
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. 6
22281684 2012
25
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). 6
22113612 2011
26
Variants in or near KITLG, BAK1, DMRT1, and TERT-CLPTM1L predispose to familial testicular germ cell tumour. 56
21617256 2011
27
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. 6
21107320 2010
28
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. 6
21107323 2010
29
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. 6
20823850 2010
30
Inhibition of mutated, activated BRAF in metastatic melanoma. 6
20818844 2010
31
LINE-1 methylation is inherited in familial testicular cancer kindreds. 56
20478068 2010
32
Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. 56
19483682 2009
33
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. 6
19042984 2008
34
Increased prevalence of testicular microlithiasis in men with familial testicular cancer and their relatives. 56
18841155 2008
35
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. 6
18398503 2008
36
Testicular microlithiasis as a familial risk factor for testicular germ cell tumour. 56
17971766 2007
37
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. 6
17785355 2007
38
BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. 6
17488796 2007
39
BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. 6
17374713 2007
40
Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. 6
16772349 2006
41
Thanatophoric dysplasia type 2 with encephalocele during the second trimester. 6
16752380 2006
42
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. 6
16174717 2005
43
High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. 6
15998781 2005
44
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. 6
16015629 2005
45
High incidence of thyroid cancer in long-standing goiters with thyroglobulin mutations. 6
16187918 2005
46
Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. 6
15687339 2005
47
The Ter mutation in the dead end gene causes germ cell loss and testicular germ cell tumours. 56
15902260 2005
48
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. 6
15342696 2004
49
Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. 6
15356022 2004
50
Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. 6
15181070 2004

Variations for Testicular Germ Cell Tumor

ClinVar genetic disease variations for Testicular Germ Cell Tumor:

6 (show all 35) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 BCL10 NM_003921.5(BCL10):c.499dup (p.Ser167fs)duplication Pathogenic 6250 rs387906350 1:85733512-85733513 1:85267829-85267830
2 BCL10 NM_003921.5(BCL10):c.172C>G (p.Arg58Gly)SNV Pathogenic 6265 rs121918314 1:85736475-85736475 1:85270792-85270792
3 BCL10 NM_003921.5(BCL10):c.172C>T (p.Arg58Ter)SNV Pathogenic 6266 rs121918314 1:85736475-85736475 1:85270792-85270792
4 STK11 NM_000455.4(STK11):c.488G>A (p.Gly163Asp)SNV Pathogenic 7448 rs137853078 19:1220395-1220395 19:1220396-1220396
5 FGFR3 NM_001163213.1(FGFR3):c.1954A>G (p.Lys652Glu)SNV Pathogenic 16331 rs78311289 4:1807889-1807889 4:1806162-1806162
6 FGFR3 NM_001163213.1(FGFR3):c.742C>T (p.Arg248Cys)SNV Pathogenic 16332 rs121913482 4:1803564-1803564 4:1801837-1801837
7 FGFR3 NM_001163213.1(FGFR3):c.1626C>G (p.Asn542Lys)SNV Pathogenic 16338 rs28933068 4:1807371-1807371 4:1805644-1805644
8 FGFR3 NM_001163213.1(FGFR3):c.746C>G (p.Ser249Cys)SNV Pathogenic 16339 rs121913483 4:1803568-1803568 4:1801841-1801841
9 FGFR3 NM_001163213.1(FGFR3):c.1955A>C (p.Lys652Thr)SNV Pathogenic 65855 rs121913105 4:1807890-1807890 4:1806163-1806163
10 BCL10 NM_003921.5(BCL10):c.488C>T (p.Thr163Met)SNV Pathogenic 30361 rs370432633 1:85733524-85733524 1:85267841-85267841
11 KIT NM_000222.2(KIT):c.2446G>C (p.Asp816His)SNV Pathogenic 13863 rs121913506 4:55599320-55599320 4:54733154-54733154
12 FGFR3 NM_001163213.1(FGFR3):c.749C>G (p.Pro250Arg)SNV Pathogenic/Likely pathogenic 16340 rs4647924 4:1803571-1803571 4:1801844-1801844
13 HRAS NM_005343.4(HRAS):c.181C>A (p.Gln61Lys)SNV Pathogenic/Likely pathogenic 12601 rs28933406 11:533875-533875 11:533875-533875
14 FGFR3 NM_001163213.1(FGFR3):c.1144G>A (p.Gly382Arg)SNV Conflicting interpretations of pathogenicity 16327 rs28931614 4:1806119-1806119 4:1804392-1804392
15 STK11 NM_000455.4(STK11):c.632G>A (p.Arg211Gln)SNV Conflicting interpretations of pathogenicity 182910 rs730881982 19:1220614-1220614 19:1220615-1220615
16 STK11 NM_000455.4(STK11):c.719C>G (p.Ser240Trp)SNV Conflicting interpretations of pathogenicity 182902 rs730881976 19:1220701-1220701 19:1220702-1220702
17 KIT NM_000222.2(KIT):c.200C>G (p.Thr67Ser)SNV Conflicting interpretations of pathogenicity 237252 rs144933028 4:55561810-55561810 4:54695644-54695644
18 KIT NM_000222.2(KIT):c.1553C>T (p.Pro518Leu)SNV Uncertain significance 237245 rs569408054 4:55593396-55593396 4:54727230-54727230
19 KIT NM_000222.2(KIT):c.2881G>A (p.Gly961Ser)SNV Uncertain significance 237271 rs773828910 4:55604673-55604673 4:54738507-54738507
20 STK11 NM_000455.4(STK11):c.1243C>G (p.Arg415Gly)SNV Uncertain significance 220264 rs864622448 19:1226587-1226587 19:1226588-1226588
21 STK11 NM_000455.4(STK11):c.566C>T (p.Thr189Ile)SNV Uncertain significance 141128 rs587781515 19:1220473-1220473 19:1220474-1220474
22 STK11 NM_000455.4(STK11):c.464+5G>ASNV Uncertain significance 141354 rs587781681 19:1219417-1219417 19:1219418-1219418
23 STK11 NM_000455.4(STK11):c.1012G>A (p.Val338Met)SNV Uncertain significance 142198 rs587782302 19:1223075-1223075 19:1223076-1223076
24 KIT NM_000222.2(KIT):c.2104C>G (p.Leu702Val)SNV Uncertain significance 409779 rs768847037 4:55595614-55595614 4:54729448-54729448
25 KIT NM_000222.2(KIT):c.2294A>G (p.Asp765Gly)SNV Uncertain significance 409730 rs1060502545 4:55598097-55598097 4:54731931-54731931
26 KIT NM_000222.2(KIT):c.2863G>T (p.Val955Leu)SNV Uncertain significance 409783 rs1060502568 4:55604655-55604655 4:54738489-54738489
27 KIT NM_000222.2(KIT):c.2887A>G (p.Thr963Ala)SNV Uncertain significance 409774 rs773709702 4:55604679-55604679 4:54738513-54738513
28 STK11 NM_000455.4(STK11):c.1195C>A (p.Gln399Lys)SNV Uncertain significance 403791 rs1060499968 19:1226539-1226539 19:1226540-1226540
29 FGFR3 NM_001163213.1(FGFR3):c.1999G>T (p.Ala667Ser)SNV Uncertain significance 465350 rs764892330 4:1808017-1808017 4:1806290-1806290
30 KIT NM_000222.2(KIT):c.2900C>G (p.Ser967Cys)SNV Uncertain significance 458936 rs1232060384 4:55604692-55604692 4:54738526-54738526
31 KIT NM_000222.2(KIT):c.302A>G (p.His101Arg)SNV Uncertain significance 458940 rs1274601103 4:55561912-55561912 4:54695746-54695746
32 KIT NM_000222.2(KIT):c.2057G>A (p.Arg686His)SNV Uncertain significance 458902 rs143772138 4:55595567-55595567 4:54729401-54729401
33 FGFR3 NM_001163213.1(FGFR3):c.2159A>G (p.Asn720Ser)SNV Uncertain significance 521225 rs139773438 4:1808395-1808395 4:1806668-1806668
34 FGFR3 NM_001163213.1(FGFR3):c.200G>A (p.Gly67Asp)SNV Uncertain significance 546226 rs369232922 4:1801071-1801071 4:1799344-1799344
35 KIT NM_000222.2(KIT):c.2836C>T (p.Arg946Ter)SNV Uncertain significance 576610 rs139000082 4:55604628-55604628 4:54738462-54738462

UniProtKB/Swiss-Prot genetic disease variations for Testicular Germ Cell Tumor:

73
# Symbol AA change Variation ID SNP ID
1 FGFR3 p.Lys650Glu VAR_004160 rs78311289
2 STK10 p.Lys277Glu VAR_023827 rs757545210
3 STK11 p.Gly163Asp VAR_033140 rs137853078

Copy number variations for Testicular Germ Cell Tumor from CNVD:

7 (show all 12)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 19332 1 149600000 247249719 Gain Testicular germ cell tumor
2 42821 10 40300000 82000000 Loss Testicular germ cell tumor
3 61421 12 1 132349534 Gain Testicular germ cell tumor
4 89303 15 17000000 76100000 Loss Testicular germ cell tumor
5 121721 18 46400000 76117153 Loss Testicular germ cell tumor
6 146937 2 56300000 230700000 Loss Testicular germ cell tumor
7 180589 4 107900000 191273063 Loss Testicular germ cell tumor
8 206877 6 149100000 170899992 Loss Testicular germ cell tumor
9 226157 7 55086724 55275030 Amplification EGFR Testicular germ cell tumor
10 245111 9 101600000 129300000 Loss Testicular germ cell tumor
11 261703 X 24900000 29400000 Gain Testicular germ cell tumor
12 262543 X 37500000 146900000 Gain Testicular germ cell tumor

Expression for Testicular Germ Cell Tumor

Search GEO for disease gene expression data for Testicular Germ Cell Tumor.

Pathways for Testicular Germ Cell Tumor

Pathways related to Testicular Germ Cell Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.19 KITLG KIT HRAS FGFR3 BCL10
2 11.92 MIR373 MIR200C MIR145 MIR133B HRAS FGFR3
3 11.28 KIT HRAS FGFR3
4 10.62 MIR373 MIR372 MIR371A MIR145
5 10.53 KITLG KIT

GO Terms for Testicular Germ Cell Tumor

Biological processes related to Testicular Germ Cell Tumor according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.89 MIR372 KITLG KIT HRAS FGFR3
2 MAPK cascade GO:0000165 9.78 KITLG KIT HRAS FGFR3
3 male gonad development GO:0008584 9.7 KITLG KIT DMRT1
4 miRNA mediated inhibition of translation GO:0035278 9.69 MIR200C MIR145 MIR133B
5 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.61 SPRY4 MIR200C MIR133B
6 positive regulation of kinase activity GO:0033674 9.58 KIT FGFR3 BCL10
7 embryonic hemopoiesis GO:0035162 9.54 KITLG KIT
8 positive regulation of MAP kinase activity GO:0043406 9.54 KITLG KIT HRAS
9 positive regulation of phospholipase C activity GO:0010863 9.46 KIT HRAS
10 protein autophosphorylation GO:0046777 9.46 STK11 STK10 KIT FGFR3
11 ectopic germ cell programmed cell death GO:0035234 9.32 KITLG KIT
12 gene silencing by miRNA GO:0035195 9.28 MIR373 MIR372 MIR371A MIR367 MIR302D MIR200C
13 germ cell migration GO:0008354 9.26 KIT DMRT1
14 negative regulation of vascular endothelial growth factor production GO:1904046 9.26 MIR373 MIR372 MIR302D MIR140

Molecular functions related to Testicular Germ Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.23 MIR373 MIR372 MIR371A MIR302D MIR200C MIR145

Sources for Testicular Germ Cell Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....